New drug BAL0891 enters human trials for Tough-to-Treat cancers
Disease control
Recruiting now
This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…
Phase: PHASE1 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC